TNF antagonists interfere with many pathways involved in RA synovial inflammatory processes; these include local production of chemokines and cytokines [6-9], vascular proliferation and endothelial expression of adhesion molecules [10,11], cell trafficking into the synovium [8], proliferation of synovial macrophages [12-14], and production of matrix metalloproteinases [15]. This evidence concerns the gene TNF and rheumatoid arthritis.